Investors
We announced our second quarter 2026 results on Tuesday, 28 July.
Press releases
- Blenrep assigned permanent billing code, supporting timely access for patients with relapsed/refractory multiple myeloma
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

GSK Global links
Visit our Global site for additional features









